Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian C Newland

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Lancet (London, England)|January 26, 2002
Treatment of adults with autoimmune thrombocytopenic purpuraAdrian C Newland
British Journal of Haematology|April 7, 2011
ITP: a historical perspectiveRoberto Stasi, Adrian C Newland
The New England Journal of Medicine|February 11, 2011
Guidelines for immune thrombocytopeniaDrew Provan, Adrian C Newland
Advances in Therapy|October 27, 2015
Current Management of Primary Immune ThrombocytopeniaDrew Provan, Adrian C Newland
Expert Opinion on Investigational Drugs|May 9, 2022
Investigational drugs for immune thrombocytopeniaDrew Provan, Adrian C Newland
British Journal of Haematology|April 1, 2015
Fatigue in immune thrombocytopeniaQuentin A Hill, Adrian C Newland
Hematology (Amsterdam, Netherlands)|June 16, 2001
Current Perspectives on the Use of Growth Factors in the Therapy of Acute Myeloid Leukaemia; MalignancyDeborah S. Richardson, Adrian C. Newland
Expert Opinion on Biological Therapy|May 21, 2013
Immune thrombocytopenia -- what are the new treatment options?Simon Hallam, Drew Provan, Adrian C Newland
Biochemical and Biophysical Research Communications|October 11, 2003
Bax conformational change is a crucial step for PUMA-mediated apoptosis in human leukemiaFeng-Ting Liu, Adrian C Newland, Li Jia
Hematology (Amsterdam, Netherlands)|December 12, 2003
Adult idiopathic thrombocytopenic purpuraAdam J Mead, Adrian C Newland, Drew Provan
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Lancet (London, England)|January 26, 2002
Treatment of adults with autoimmune thrombocytopenic purpuraAdrian C Newland
British Journal of Haematology|April 7, 2011
ITP: a historical perspectiveRoberto Stasi, Adrian C Newland
The New England Journal of Medicine|February 11, 2011
Guidelines for immune thrombocytopeniaDrew Provan, Adrian C Newland
Advances in Therapy|October 27, 2015
Current Management of Primary Immune ThrombocytopeniaDrew Provan, Adrian C Newland
Expert Opinion on Investigational Drugs|May 9, 2022
Investigational drugs for immune thrombocytopeniaDrew Provan, Adrian C Newland
British Journal of Haematology|April 1, 2015
Fatigue in immune thrombocytopeniaQuentin A Hill, Adrian C Newland
Hematology (Amsterdam, Netherlands)|June 16, 2001
Current Perspectives on the Use of Growth Factors in the Therapy of Acute Myeloid Leukaemia; MalignancyDeborah S. Richardson, Adrian C. Newland
Expert Opinion on Biological Therapy|May 21, 2013
Immune thrombocytopenia -- what are the new treatment options?Simon Hallam, Drew Provan, Adrian C Newland
Biochemical and Biophysical Research Communications|October 11, 2003
Bax conformational change is a crucial step for PUMA-mediated apoptosis in human leukemiaFeng-Ting Liu, Adrian C Newland, Li Jia
Hematology (Amsterdam, Netherlands)|December 12, 2003
Adult idiopathic thrombocytopenic purpuraAdam J Mead, Adrian C Newland, Drew Provan
Pageof 6